| Trial ID # | NCT02511795 |
| Phase | Ib |
| Drug Class | DNA Damage Repair Pathway Inhibitors: PARP |
| Drug Name | Olaparib |
| Alternate Drug Names | AZD2281, Lynparza |
| Drugs in Trial | Adavosertib, Olaparib |
| Eligible Participant | Recurrent ovarian cancer (no prior PARP inhibitor) |
| Patients Enrolled | 119 (26 ovarian) |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DCR, evaluated per RECIST |
| Efficacy | RP2D once daily (qd) dosing: adavosertib 200 mg qd 3/4 days for 2/3 weeks+olaparib 200 mg bid 26 ovarian w/ adavosertib qd or bid dosing: ORR: 15% (3PR - 1 BRCA MUT, n=20) 1 ovarian at qd RP2D dosing: 1SD |
| Clinically Significant Adverse Events | Serious AE: 1 sepsis |
| Conclusion | Olaparib+adavosertib shows antitumor activity, particularly at the twice daily (BID) schedule |
| Reference | Hamilton E et al. Phase Ib study of adavosertib in combination with olaparib in patients with refractory solid tumors: Dose escalation. Cancer Res (2019) 79(13 Suppl):abstr CT025 Hamilton E et al. Phase Ib study of adavosertib in combination with olaparib in patients with refractory solid tumors: Dose escalation. Poster |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.